Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for ...

Both Donanemab and Lecanemab are antibody drugs that binds to amyloid ... Potential eligible patients would need to have a baseline MRI scan and then either a PET-CT scan or lumbar puncture to confirm ...

NHS spending watchdog says donanemab - available to 70,000 people in England and Wales - 'does not currently demonstrate ...

A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...

Patient Peter Almond told of his disappointment that donanemab will only be available to those who can pay for a private ...

Eli Lilly invests £279M in the UK to boost life sciences, while its Alzheimer's drug, donanemab, faces European regulatory ...

Such change has also been supported by a bipartisan group of 14 U.S. senators, led by Marsha Blackburn, which sent a letter to CMS on June 20, 2024, requesting increased patient access to PET and ...

The field's rapid advances make securing reimbursement an important area of focus, researchers in a recent commentary argued.